In older persons, does daily folic acid supplementation for 3 years improve cognitive function?
M a i n r e s u l t s
At 3 years, the folic acid group improved more than the placebo group for global cognitive function and memory and declined less for information-processing speed (Table) .
Groups did not differ for change in sensorymotor speed, complex speed, and word fluency (Table) .
C o n c l u s i o n
Daily folic acid supplementation for 3 years improved some aspects of cognitive function in older persons. 
C o m m e n t a r y
Despite suggestive epidemiologic associations, trials of supplementation with folate, vitamin B 12 , or both to reduce homocysteine levels have shown little effect on cognitive performance in older persons (1, 2) . In the FACIT trial by Durga and colleagues, participants 50 to 70 years of age with elevated homocysteine levels were randomized to treatment with folate or placebo for a longer time than in previous studies. Those in the folate group showed better results for speed of information processing and memory. Several factors, including the small effect size and strict inclusion criteria, limit the clinical relevance and generalizability of results. That some participants were functionally deficient in folate was shown by the decline in homocysteine levels following folate supplementation. Post hoc subgroup analyses showed that the effects of folate were greater in participants who had vitamin B 12 levels < 250 pmol/L. These levels are often associated with occult vitamin B 12 deficiency, and consequently, high homocysteine levels. Without measuring the level of methylmalonic acid, it is unclear whether this subgroup was also functionally deficient in vitamin B 12 .
The results of the FACIT trial may not apply to persons in the United States and Canada, where food is fortified with folic acid. 27% of all participants screened for this trial had homocysteine levels ≥ 13 µmol/L. For U.S. women of similar age, 13.2 µmol/L is the 95th percentile of homocysteine levels, whereas 10.74 µmol/L is the 75th percentile and 14.99 µmol/L is the 95th percentile for men (3) . The results of the FACIT trial require replication with further elucidation of the populations who might benefit from folic acid supplementation. 
